Global Competition Review (GCR) has ranked Goodwin as an Elite firm in Massachusetts in the 2023 edition of the GCR 100. For over two decades, GCR 100 has conducted in-depth research to provide a quantitative and qualitative analysis that takes into account the size, activity and reputation of a firm’s antitrust practice in order to recognize the law firms doing the most important antitrust work around the world.
Featuring standout Massachusetts-based practitioners such as Christopher Holding, Alicia Rubio-Spring and Simone Waterbury, the GCR 100 publication called attention to Goodwin’s successes over the past year. Noted highlights include securing the dismissal of claims from multiple classes against Teva Pharmaceuticals and Watson Laboratories in New York Federal Court and securing the dismissal of claims that Frazier Healthcare and other entities violated the Clayton Antitrust Act by acquiring a rival and reducing its output to gain a competitive edge. It also noted the firm’s successful representation of Nimbus Therapeutics in both a monopolization case and in fending off an attempted hostile purchase of a Nimbus pipeline drug, which received a second request from the Federal Trade Commission.
Goodwin’s Antitrust & Competition team, under the leadership of co-chairs Andrew Lacy and Arman Oruc, has exceptional experience advising clients ranging from the largest Fortune 500 companies to emerging growth companies on transactions before U.S. and international antitrust agencies. Our practice stands out for its high volume of work in the life sciences, technology and private equity industries including merger clearance work and strategic litigation.
To learn more about Goodwin’s ranking, visit GCR 100.